Benzinga Pro data, Fulcrum Therapeutics FULC reported Q2 sales of $4.38 million. Earnings fell to a loss of $19.68 million, resulting in a 15.48% decrease from last quarter. Fulcrum Therapeutics collected $4.79 million in revenue during Q1, but reported earnings showed a $17.04 million loss.
What Is Return On Capital Employed?
Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Fulcrum Therapeutics posted an ROCE of -0.18%.
Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.
ROCE is a powerful metric for comparing the effectiveness of capital allocation for similar companies. A relatively high ROCE shows Fulcrum Therapeutics is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and, ultimately, earnings per share (EPS) growth.
For Fulcrum Therapeutics, a negative ROCE ratio of -0.18% suggests that management may not be effectively allocating their capital.Effective capital allocation is a positive indicator that a company will achieve more durable success and favorable long-term returns; poor capital allocation can be a leech on the performance of a company over time.
Fulcrum Therapeutics reported Q2 earnings per share at $-0.6/share, which beat analyst predictions of $-0.62/share.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.